Stock RPRX ROYALTY PHARMA PLC
Add to a list
To use this feature you must be a member
Log inSign up

All News Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Market Closed - Nasdaq
Other stock markets
 21:00:00 21/06/2024 BST 		5-day change 1st Jan Change
26.91 USD +1.05% Intraday chart for Royalty Pharma plc -0.04% -4.20%
06-18 Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director CI
06-17 Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Royalty Pharma : Goldman Sachs Healthcare Conference Transcript
PU
Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director
CI
Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director
CI
Transcript : Royalty Pharma plc Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:00 PM
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
GL
Royalty Pharma Prices $1.5 Billion Debt Offering
MT
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
GL
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
CI
Novartis data42 AG completed the acquisition of MorphoSys AG from group of shareholders.
CI
Royalty Pharma : Vorasidenib Transaction Call Transcript
PU
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday
MT
Royalty Pharma : Vorasidenib Transaction Press Release
PU
Agios Pharmaceuticals to Sell 15% Vorasidenib Royalty Rights to Royalty Pharma for $905 Million
MT
Transcript : Royalty Pharma plc - Special Call
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
GL
Royalty Pharma : BofA Health Care Conference Transcript
PU
Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline
MT
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
GL
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
AQ
Cytokinetics, Incorporated announced that it has received $49.999992 million in funding from Royalty Pharma plc
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RPRX Stock
  4. News Royalty Pharma plc